09/21/2026
An international team of scientists was analyzing results from a phase 2 clinical trial when they found something surprising: people with pre-cancer blood disorders and early-stage blood cancers who took daily doses of 1,000 mg oral vitamin C were significantly more likely to be alive after nearly three years of follow up than those who received a placebo.
The results, which must be confirmed by a larger clinical trial, point toward future opportunities to improve patient outcomes. The trial was led by the Van Andel Institute–Stand Up To Cancer® Epigenetics Dream Team.
“We are tremendously excited and cautiously optimistic that our results could one day translate into a simple way to improve care and outcomes for people with pre-leukemia disorders,” said VAI Distinguished Professor Dr. Peter A. Jones, co-corresponding author of the study and co-leader of the team.
Read more at the link in the comments.